Antibody therapy points to a new treatment era for primary membranous nephropathy Two year trial results position Gazyva as a potential first approved therapy for an autoimmune kidney disease with longstanding unmet need. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/antibody-therapy-points-to-a-new-treatment-era-for-primary-membranous-nephropathy-17262 Primary membranous nephropathy (pMN) is a kidney-specific autoimmune disease characterized by heavy proteinuria and immune-mediated injury to the glomeruli, the kidney’s microscopic filters. It is a leading cause of nephrotic syndrome in nondiabetic adults worldwide, accounting for 20-37 percent of cases in most reports and up to 40 percent in adults over 60